On Dec. 22, 2020, RedHill Biopharma announced that the global Phase 2/3 study with orally-administered opaganib (Yeliva, ABC294640)1 in patients hospitalized with severe COVID-19 pneumonia had received a second unanimous recommendation to continue, following a second independent Data Safety Monitoring Board (DSMB) safety review.

The DSMBﾒs recommendation was based on an analysis of unblinded safety data from the first 155 patients treated for 14 days.